Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications

Cytotherapy

Volumn 17, Issue 2, 2015, Pages 128-139

  Wuchter, Patrick ^a   Bieback, Karen ^b   Schrezenmeier, Hubert ^c   Bornhäuser, Martin ^d   Müller, Lutz P ^e   Bönig, Halvard ^f   Wagner, Wolfgang ^g   Meisel, Roland ^h   Pavel, Petra ⁱ   Tonn, Torsten ^j   Lang, Peter ^k   Müller, Ingo ^l   Renner, Matthias ^m   Malcherek, Georg ^a   Saffrich, Rainer ^a   Buss, Eike C ^a   Horn, Patrick ^a   Rojewski, Markus ^c   Schmitt, Anita ^a   Ho, Anthony D ^a   Sanzenbacher, Ralf ^c   Schmitt, Michael ^a   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Institute of Transfusion Medicine   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^f GOETHE UNIVERSITY   (Germany)

^g RWTH AACHEN UNIVERSITY   (Germany)

^h Department of Orthopedic Surgery   (Germany)

ⁱ Heidelberg GmbH   (Germany)

^j Red Cross Donor Service Sachsen   (Germany)

^k UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^l UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^m PAUL EHRLICH INSTITUT   (Germany)

more..

Author keywords

Cell based therapy; Good Manufacturing Practice; Manufacturing license; Mesenchymal stromal cells; Standardization

Indexed keywords

AGING; BONE MARROW CELL; BONE MARROW DERIVED MESENCHYMAL STROMA CELL; CELL COMPOSITION; CELL THERAPY; CONSENSUS; CULTURE MEDIUM; EUROPEAN UNION; GERMANY; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LICENCE; MALIGNANT TRANSFORMATION; MESENCHYMAL STEM CELL; MESENCHYMAL STROMA CELL; QUALITY CONTROL; REVIEW; STANDARDIZATION; STEM CELL CULTURE; ADOPTIVE IMMUNOTHERAPY; BONE MARROW; CELL CULTURE TECHNIQUE; CYTOLOGY; MESENCHYMAL STEM CELL TRANSPLANTATION; PROCEDURES; PROTOCOL COMPLIANCE; REGENERATIVE MEDICINE; STANDARDS;

CULTURE MEDIUM;

BONE MARROW; CELL CULTURE TECHNIQUES; CULTURE MEDIA; GERMANY; GUIDELINE ADHERENCE; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; QUALITY CONTROL; REGENERATIVE MEDICINE;

EID: 84922568930     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.04.002     Document Type: Review

References (114)

1. Horwitz E.M., Le Blanc K., Dominici M., Mueller I., Slaper-Cortenbach I., Marini F.C., et al. Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy 2005, 7:393-395.
2. Bianco P., Robey P.G., Simmons P.J. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2008, 2:313-319.
3. Gottschling S., Saffrich R., Seckinger A., Krause U., Horsch K., Miesala K., et al. Human mesenchymal stromal cells regulate initial self-renewing divisions of hematopoietic progenitor cells by a beta1-integrin-dependent mechanism. Stem Cells 2007, 25:798-806.
4. Wagner W., Roderburg C., Wein F., Diehlmann A., Frankhauser M., Schubert R., et al. Molecular and secretory profiles of human mesenchymal stromal cells and their abilities to maintain primitive hematopoietic progenitors. Stem Cells 2007, 25:2638-2647.
5. Alakel N., Jing D., Muller K., Bornhauser M., Ehninger G., Ordemann R. Direct contact with mesenchymal stromal cells affects migratory behavior and gene expression profile of CD133+ hematopoietic stem cells during ex vivo expansion. Exp Hematol 2009, 37:504-513.
6. Jing D., Fonseca A.V., Alakel N., Fierro F.A., Muller K., Bornhauser M., et al. Hematopoietic stem cells in co-culture with mesenchymal stromal cells: modeling the niche compartments in vitro. Haematologica 2010, 95:542-550.
7. Mendez-Ferrer S., Michurina T.V., Ferraro F., Mazloom A.R., Macarthur B.D., Lira S.A., et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010, 466:829-834.
8. Wein F., Pietsch L., Saffrich R., Wuchter P., Walenda T., Bork S., et al. N-cadherin is expressed on human hematopoietic progenitor cells and mediates interaction with human mesenchymal stromal cells. Stem Cell Res 2010, 4:129-139.
9. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E., Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003, 57:11-20.
10. Zhou K., Zhang H., Jin O., Feng X., Yao G., Hou Y., et al. Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol 2008, 5:417-424.
11. Bouffi C., Bony C., Courties G., Jorgensen C., Noel D. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PloS One 2010, 5:e14247.
12. Waterman R.S., Tomchuck S.L., Henkle S.L., Betancourt A.M. Anew mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PloS One 2010, 5:e10088.
13. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
14. Sun L., Akiyama K., Zhang H., Yamaza T., Hou Y., Zhao S., et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009, 27:1421-1432.
15. Karussis D., Karageorgiou C., Vaknin-Dembinsky A., Gowda-Kurkalli B., Gomori J.M., Kassis I., et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010, 67:1187-1194.
16. Liang J., Zhang H., Hua B., Wang H., Lu L., Shi S., et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis 2010, 69:1423-1429.
17. Keyszer G., Christopeit M., Fick S., Schendel M., Taute B.M., Behre G., et al. Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: report of five cases. Arthritis Rheum 2011, 63:2540-2542.
18. Wuchter P., Boda-Heggemann J., Straub B.K., Grund C., Kuhn C., Krause U., et al. Processus and recessus adhaerentes: giant adherens cell junction systems connect and attract human mesenchymal stem cells. Cell Tissue Res 2007, 328:499-514.
19. Wagner W., Wein F., Seckinger A., Frankhauser M., Wirkner U., Krause U., et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 2005, 33:1402-1416.
20. Kern S., Eichler H., Stoeve J., Kluter H., Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006, 24:1294-1301.
21. Wagner W., Feldmann R.E., Seckinger A., Maurer M.H., Wein F., Blake J., et al. The heterogeneity of human mesenchymal stem cell preparations: evidence from simultaneous analysis of proteomes and transcriptomes. Exp Hematol 2006, 34:536-548.
22. Ho A.D., Wagner W., Franke W. Heterogeneity of mesenchymal stromal cell preparations. Cytotherapy 2008, 10:320-330.
23. Bieback K., Hecker A., Schlechter T., Hofmann I., Brousos N., Redmer T., et al. Replicative aging and differentiation potential of human adipose tissue-derived mesenchymal stromal cells expanded in pooled human or fetal bovine serum. Cytotherapy 2012, 14:570-583.
24. Wagner W. Senescence is heterogeneous in mesenchymal stromal cells: kaleidoscopes for cellular aging. Cell Cycle 2010, 9:2923-2924.
25. Bieback K., Wuchter P., Besser D., Franke W., Becker M., Ott M., et al. Mesenchymal stromal cells (MSCs): science and f(r)iction. JMol Med 2012, 90:773-782.
26. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells: the International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
27. EudraLex The Rules Governing Medicinal Products in the European Union: EU Guidelines to Good Manufacturing Practice - Medicinal Products for Human and Veterinary Use SANCO/C8/AM/sl/ares(2010)1064597.
28. Bianco P., Barker R., Brustle O., Cattaneo E., Clevers H., Daley G.Q., et al. Regulation of stem cell therapies under attack in Europe: for whom the bell tolls. EMBO J 2013, 32:1489-1495.
29. Bernardi M., Albiero E., Alghisi A., Chieregato K., Lievore C., Madeo D., et al. Production of human platelet lysate by use of ultrasound for ex vivo expansion of human bone marrow-derived mesenchymal stromal cells. Cytotherapy 2013, 15:920-929.
30. Balci D., Can A. The assessment of cryopreservation conditions for human umbilical cord stroma-derived mesenchymal stem cells towards a potential use for stem cell banking. Curr Stem Cell Res Ther 2013, 8:60-72.
31. Sensebe L., Bourin P., Tarte K. Good manufacturing practices production of mesenchymal stem/stromal cells. Hum Gene Ther 2011, 22:19-26.
32. Reinhardt J., Stuhler A., Blumel J. Safety of bovine sera for production of mesenchymal stem cells for therapeutic use. Hum Gene Ther 2011, 22:775-776.
33. European Medicines Agency (EMA) / Committee for Medicinal Products for Human Use (CHMP) Guideline on the use of bovine serum in the manufacture of human biological medicinal products 2013. EMA/CHMP/BWP/457920/2012 rev 1.
34. Kinzebach S., Bieback K. Expansion of mesenchymal stem/stromal cells under xenogenic-free culture conditions. Adv Biochem Eng Biotechnol 2013, 129:33-57.
35. Kocaoemer A., Kern S., Kluter H., Bieback K. Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells 2007, 25:1270-1278.
36. Bieback K., Hecker A., Kocaomer A., Lannert H., Schallmoser K., Strunk D., et al. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 2009, 27:2331-2341.
37. Fekete N., Rojewski M.T., Lotfi R., Schrezenmeier H. Essential components for ex vivo proliferation of mesenchymal stromal cells. Tissue Eng Part C Methods 2014 Feb, 20(2):129-139.
38. Muller I., Kordowich S., Holzwarth C., Spano C., Isensee G., Staiber A., et al. Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy 2006, 8:437-444.
39. Schallmoser K., Rohde E., Bartmann C., Obenauf A.C., Reinisch A., Strunk D. Platelet-derived growth factors for GMP-compliant propagation of mesenchymal stromal cells. Biomed Mater Eng 2009, 19:271-276.
40. Schallmoser K., Strunk D. Generation of a pool of human platelet lysate and efficient use in cell culture. Methods Mol Biol 2013, 946:349-362.
41. Schallmoser K., Bartmann C., Rohde E., Reinisch A., Kashofer K., Stadelmeyer E., et al. Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion 2007, 47:1436-1446.
42. Fekete N., Gadelorge M., Furst D., Maurer C., Dausend J., Fleury-Cappellesso S., et al. Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components. Cytotherapy 2012, 14:540-554.
43. Schrezenmeier H., Seifried E. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred?. Vox Sang 2010, 99:1-15.
44. Rauch C., Feifel E., Amann E.M., Spotl H.P., Schennach H., Pfaller W., et al. Alternatives to the use of fetal bovine serum: human platelet lysates as a serum substitute in cell culture media. Altex 2011, 28:305-316.
45. Crespo-Diaz R., Behfar A., Butler G.W., Padley D.J., Sarr M.G., Bartunek J., et al. Platelet lysate consisting of a natural repair proteome supports human mesenchymal stem cell proliferation and chromosomal stability. Cell Transplant 2011, 20:797-811.
46. Dahl J.A., Duggal S., Coulston N., Millar D., Melki J., Shahdadfar A., et al. Genetic and epigenetic instability of human bone marrow mesenchymal stem cells expanded in autologous serum or fetal bovine serum. Int J Dev Biol 2008, 52:1033-1042.
47. Lange C., Cakiroglu F., Spiess A.N., Cappallo-Obermann H., Dierlamm J., Zander A.R. Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine. JCell Physiol 2007, 213:18-26.
48. Bieback K., Ha V.A., Hecker A., Grassl M., Kinzebach S., Solz H., et al. Altered gene expression in human adipose stem cells cultured with fetal bovine serum compared to human supplements. Tissue Eng Part A 2010, 16:3467-3484.
49. Dreher L., Elvers-Hornung S., Brinkmann I., Huck V., Henschler R., Gloe T., et al. Cultivation in human serum reduces adipose tissue-derived mesenchymal stromal cell adhesion to laminin and endothelium and reduces capillary entrapment. Stem Cells Dev 2013, 22:791-803.
50. Lucchini G., Introna M., Dander E., Rovelli A., Balduzzi A., Bonanomi S., et al. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant 2010, 16:1293-1301.
51. Furlani D., Ugurlucan M., Ong L., Bieback K., Pittermann E., Westien I., et al. Is the intravascular administration of mesenchymal stem cells safe? Mesenchymal stem cells and intravital microscopy. Microvasc Res 2009, 77:370-376.
52. Ramot Y., Steiner M., Morad V., Leibovitch S., Amouyal N., Cesta M.F., et al. Pulmonary thrombosis in the mouse following intravenous administration of quantum dot-labeled mesenchymal cells. Nanotoxicology 2010, 4:98-105.
53. Lee R.H., Pulin A.A., Seo M.J., Kota D.J., Ylostalo J., Larson B.L., et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009, 5:54-63.
54. Cooper K., Viswanathan C. Establishment of a mesenchymal stem cell bank. Stem Cells Int 2011, 2011:905621.
55. Fekete N., Rojewski M.T., Furst D., Kreja L., Ignatius A., Dausend J., et al. GMP-compliant isolation and large-scale expansion of bone marrow-derived MSC. PLoS One 2012, 7:e43255.
56. Rojewski M.T., Fekete N., Baila S., Nguyen K., Fürst D., Antwiler D., Dausend J., Kreja L., Ignatius A., Sensebé L., Schrezenmeier H., et al. GMP-compliant isolation and expansion of bone marrow-derived MSCs in the closed, automated device quantum cell expansion system. Cell Transplant 2013, 22(11):1981-2000.
57. Rojewski M.T., Weber B.M., Schrezenmeier H. Phenotypic characterization of mesenchymal stem cells from various tissues. Transfus Med Hemother 2008, 35:168-184.
58. Abdelrazik H., Spaggiari G.M., Chiossone L., Moretta L. Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitory capacity on T- and NK-cell proliferation and function. Eur J Immunol 2011, 41:3281-3290.
59. Cheng P., Gao Z.Q., Liu Y.H., Xue Y.X. Platelet-derived growth factor BB promotes the migration of bone marrow-derived mesenchymal stem cells towards C6 glioma and up-regulates the expression of intracellular adhesion molecule-1. Neurosci Lett 2009, 451:52-56.
60. Menard C., Tarte K. Immunoregulatory properties of clinical grade mesenchymal stromal cells: evidence, uncertainties, and clinical application. Stem Cell Res Ther 2013, 4:64.
61. Varin A., Pontikoglou C., Labat E., Deschaseaux F., Sensebe L. CD200R/CD200 inhibits osteoclastogenesis: new mechanism of osteoclast control by mesenchymal stem cells in human. PLoS One 2013, 8:e72831.
62. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008, 8:726-736.
63. Prockop D.J., Oh J.Y. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther 2012, 20:14-20.
64. Xu J., Wang D., Liu D., Fan Z., Zhang H., Liu O., et al. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjogren syndrome. Blood 2012, 120:3142-3151.
65. Guiducci S., Porta F., Saccardi R., Guidi S., Ibba-Manneschi L., Manetti M., et al. Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis: a case report. Ann Intern Med 2010, 153:650-654.
66. Zhou H., Guo M., Bian C., Sun Z., Yang Z., Zeng Y., et al. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. Biol Blood Marrow Transplant 2010, 16:403-412.
67. Weng J.Y., Du X., Geng S.X., Peng Y.W., Wang Z., Lu Z.S., et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant 2010, 45:1732-1740.
68. Baron F., Storb R. Mesenchymal stromal cells: a new tool against graft-versus-host disease?. Biol Blood Marrow Transplant 2012, 18:822-840.
69. Muller I., Kordowich S., Holzwarth C., Isensee G., Lang P., Neunhoeffer F., et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis 2008, 40:25-32.
70. Kebriaei P., Isola L., Bahceci E., Holland K., Rowley S., McGuirk J., et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009, 15:804-811.
71. Allison M. Genzyme backs Osiris, despite Prochymal flop. Nat Biotechnol 2009, 27:966-967.
72. Martin P.J., Uberti J.P., Soiffer R.J., Klingemann H., Waller E.K., Daly A.S., et al. Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase III trial in GVHD. Biol Blood Marrow Transplant 2010, 16(Suppl 2):S169-S170.
73. Prasad V.K., Lucas K.G., Kleiner G.I., Talano J.A., Jacobsohn D., Broadwater G., et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 2011, 17:534-541.
74. Menard C., Pacelli L., Bassi G., Dulong J., Bifari F., Bezier I., et al. Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. Stem Cells Dev 2013, 22:1789-1801.
75. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
76. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
77. Melief S.M., Geutskens S.B., Fibbe W.E., Roelofs H. Multipotent stromal cells skew monocytes towards an anti-inflammatory interleukin-10-producing phenotype by production of interleukin-6. Haematologica 2013, 98:888-895.
78. Meisel R., Zibert A., Laryea M., Gobel U., Daubener W., Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103:4619-4621.
79. Duijvestein M., Wildenberg M.E., Welling M.M., Hennink S., Molendijk I., van Zuylen V.L., et al. Pretreatment with interferon-gamma enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells 2011, 29:1549-1558.
80. Spaggiari G.M., Abdelrazik H., Becchetti F., Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 2009, 113:6576-6583.
81. Gieseke F., Bohringer J., Bussolari R., Dominici M., Handgretinger R., Muller I. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood 2010, 116:3770-3779.
82. Akiyama K., Chen C., Wang D., Xu X., Qu C., Yamaza T., et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell 2012, 10:544-555.
83. Rizzo R., Lanzoni G., Stignani M., Campioni D., Alviano F., Ricci F., et al. Asimple method for identifying bone marrow mesenchymal stromal cells with a high immunosuppressive potential. Cytotherapy 2011, 13:523-527.
84. Flemming A., Schallmoser K., Strunk D., Stolk M., Volk H.D., Seifert M. Immunomodulative efficacy of bone marrow-derived mesenchymal stem cells cultured in human platelet lysate. JClin Immunol 2011, 31:1143-1156.
85. Capelli C., Domenghini M., Borleri G., Bellavita P., Poma R., Carobbio A., et al. Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. Bone Marrow Transplant 2007, 40:785-791.
86. Rasmusson I., Ringden O., Sundberg B., Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003, 76:1208-1213.
87. Lin Y., Hogan W.J. Clinical Application of mesenchymal stem cells in the treatment and prevention of graft-versus-host disease. Adv Hematol 2011, 2011:427863.
88. Karlsson H., Samarasinghe S., Ball L.M., Sundberg B., Lankester A.C., Dazzi F., et al. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood 2008, 112:532-541.
89. von Bahr L., Sundberg B., Lonnies L., Sander B., Karbach H., Hagglund H., et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 2012, 18:557-564.
90. Fasslrinner F., Wobus M., Duryagina R., Muller K., Stopp S., Wehner R., et al. Differential effects of mixed lymphocyte reaction supernatant on human mesenchymal stromal cells. Exp Hematol 2012, 40:934-944.
91. Mamidi M.K., Nathan K.G., Singh G., Thrichelvam S.T., Mohd Yusof N.A., Fakharuzi N.A., et al. Comparative cellular and molecular analyses of pooled bone marrow multipotent mesenchymal stromal cells during continuous passaging and after successive cryopreservation. JCell Biochem 2012, 113:3153-3164.
92. Samuelsson H., Ringden O., Lonnies H., Le Blanc K. Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells. Cytotherapy 2009, 11:129-136.
93. Francois M., Copland I.B., Yuan S., Romieu-Mourez R., Waller E.K., Galipeau J. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-gamma licensing. Cytotherapy 2012, 14:147-152.
94. Prockop D.J., Brenner M., Fibbe W.E., Horwitz E., Le Blanc K., Phinney D.G., et al. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy 2010, 12:576-578.
95. Rubio D., Garcia S., De la Cueva T., Paz M.F., Lloyd A.C., Bernad A., et al. Human mesenchymal stem cell transformation is associated with a mesenchymal-epithelial transition. Exp Cell Res 2008, 314:691-698.
96. Torsvik A., Rosland G.V., Svendsen A., Molven A., Immervoll H., McCormack E., et al. Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track: letter. Cancer Res 2010, 70:6393-6396.
97. Rubio D., Garcia-Castro J., Martin M.C., de la Fuente R., Cigudosa J.C., Lloyd A.C., et al. Spontaneous human adult stem cell transformation. Cancer Res 2005, 65:3035-3039.
98. de la Fuente R., Bernad A., Garcia-Castro J., Martin M.C., Cigudosa J.C. Retraction: spontaneous human adult stem cell transformation. Cancer Res 2010, 70:6682.
99. Tarte K., Gaillard J., Lataillade J.J., Fouillard L., Becker M., Mossafa H., et al. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 2010, 115:1549-1553.
100. Barkholt L., Flory E., Jekerle V., Lucas-Samuel S., Ahnert P., Bisset L., et al. Risk of tumorigenicity in mesenchymal stromal cell-based therapies: bridging scientific observations and regulatory viewpoints. Cytotherapy 2013, 15:753-759.
101. Mueller L.P., Luetzkendorf J., Mueller T., Reichelt K., Simon H., Schmoll H.J. Presence of mesenchymal stem cells in human bone marrow after exposure to chemotherapy: evidence of resistance to apoptosis induction. Stem Cells 2006, 24:2753-2765.
102. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965, 37:614-636.
103. Schellenberg A., Stiehl T., Horn P., Joussen S., Pallua N., Ho A.D., et al. Population dynamics of mesenchymal stromal cells during culture expansion. Cytotherapy 2012, 14:401-411.
104. Wagner W., Ho A.D., Zenke M. Different facets of aging in human mesenchymal stem cells. Tissue Eng Part B Reviews 2010, 16:445-453.
105. Wagner W., Bork S., Lepperdinger G., Joussen S., Ma N., Strunk D., et al. How to track cellular aging of mesenchymal stromal cells?. Aging 2010, 2:224-230.
106. Allsopp R.C., Vaziri H., Patterson C., Goldstein S., Younglai E.V., Futcher A.B., et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A 1992, 89:10114-10118.
107. Baxter M.A., Wynn R.F., Jowitt S.N., Wraith J.E., Fairbairn L.J., Bellantuono I. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells 2004, 22:675-682.
108. Fehrer C., Voglauer R., Wieser M., Pfister G., Brunauer R., Cioca D., et al. Techniques in gerontology: cell lines as standards for telomere length and telomerase activity assessment. Exp Gerontol 2006, 41:648-651.
109. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., et al. Abiomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995, 92:9363-9367.
110. Bork S., Pfister S., Witt H., Horn P., Korn B., Ho A.D., et al. DNA methylation pattern changes upon long-term culture and aging of human mesenchymal stromal cells. Aging Cell 2010, 9:54-63.
111. Redaelli S., Bentivegna A., Foudah D., Miloso M., Redondo J., Riva G., et al. From cytogenomic to epigenomic profiles: monitoring the biologic behavior of in vitro cultured human bone marrow mesenchymal stem cells. Stem Cell Res Ther 2012, 3:47.
112. Koch C.M., Reck K., Shao K., Lin Q., Joussen S., Ziegler P., et al. Pluripotent stem cells escape from senescence-associated DNA methylation changes. Genome Res 2013, 23:248-259.
113. Koch C.M., Joussen S., Schellenberg A., Lin Q., Zenke M., Wagner W. Monitoring of cellular senescence by DNA-methylation at specific CpG sites. Aging Cell 2012, 11:366-369.
114. Koch C.M., Wagner W. Epigenetic biomarker to determine replicative senescence of cultured cells. Methods Mol Biol 2013, 1048:309-321.